Key facts
- This page summarizes Darin Lippoldt's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Jan 2026, 16:18.
Darin Lippoldt - 08 Jan 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)
- Reporting relationship
- Chief Legal Officer
- Issuer ticker
- NBIX
- Reported as of
- 08 Jan 2026
- Net transaction value
- +$120,531
- SEC form
- 4
- Accepted by SEC
- 12 Jan 2026, 16:18:03 UTC
- Prior SEC filing
- 10 Dec 2025
- Next SEC filing
- 03 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darin Lippoldt
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Darin Lippoldt filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 12 Jan 2026.
Change
- Previous filing in this sequence was filed on 10 Dec 2025.
- Current net transaction value: +$120,531.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001504783
Primary reporting owner
Lippoldt Darin
- Relationship
- Chief Legal Officer
- Address
- 6027 EDGEWOOD BEND CT., SAN DIEGO
- Signature
- /s/ Darin Lippoldt
- Signature date
- 12 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NBIX
transaction
Common Stock
Options Exercise
- Transaction value
- $120,531
- Shares
- +3,349
- Change %
- +7.7%
- Price
- $35.99
- Shares after
- 46,754
- Date
- 08 Jan 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NBIX
transaction
Derivative
Incentive Stock Option
Options Exercise
- Transaction value
- $0
- Shares
- -3,349
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 08 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,349
- Exercise price
- $35.99
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option was granted February 5, 2016 and vested monthly over four years. These options were due to expire on February 5, 2026.